Acne vulgaris is a chronic inflammatory dermatosis which is notable for open and/or closed comedones (blackheads and whiteheads) and inflammatory lesions including papules, pustules or nodules.
Mild acne has <20 comedones or <15 inflammatory lesions or <30 total lesion count.
Moderate acne has 20-100 comedones or 15-20 inflammatory lesions or 30-125 total lesion count.
Severe papules/pustules or nodulocystic acne is the acne resistant to topical treatment or if scarring/nodular lesions are present.


  • Acne vulgaris is a chronic inflammatory dermatosis which is notable for open and/or closed comedones (blackheads & whiteheads) and inflammatory lesions including papules, pustules, or nodules

Risk Factors

Contributing Factors

  • Medications
    • Corticosteroids, anabolic steroids, Lithium, some OC, etc
  • Androgen excess
    • Signs of androgen excess: Precocious puberty, hirsutism, irregular menstruation, androgenetic alopecia
    • Causes of androgen excess: Polycystic ovary disease or adrenal, ovarian, or pituitary tumor
    • Pathogenesis: Androgen excess causes abnormal epithelial desquamation and obstruction of follicles, the latter secondary to sebum production forming open and closed comedones. Propionibacterium acne proliferates due to sebum and causes inflammation manifested as papules, pustules, nodules, and cysts
  • Mechanical
    • Physical occlusion: Eg cosmetics, hats, head bands, etc
  • Other factors for which evidence is limited
    • Consumption of westernized diet, intake of skim milk, stress
Editor's Recommendations
Most Read Articles
6 months ago
An early and proper therapeutic strategy for acquired cold urticaria (ACU) will only be possible by knowing the clinical predictors of the disease evolution and the clinical features of ACU phenotypes, according to a recent study.
3 months ago
Atopic dermatitis is a chronic, relapsing, pruritic inflammatory skin disease that affects many children and adults. The goal of this activity is to educate pharmacists on atopic dermatitis and the available pharmacotherapies. 
Please click here to access the module. 
10 months ago
Bilastine is a novel second-generation antihistamine that optimizes the treatment of chronic urticaria and allergic rhinitis by effectively balancing its symptom-relieving effects with a unique safety profile. At the recent European Academy of Allergy and Clinical Immunology (EAACI) Congress held in Vienna, Austria, Professor Marcus Maurer of the Charité-Universitätsmedizen, Berlin, Germany, and Associate Professor Marysia Recto of the Asian Hospital and Medical Centre, Muntinlupa City, Philippines, outlined bilastine’s effects on patients with chronic urticaria and allergic rhinitis, while Professor Piotr Kuna from the Medical University of Lodz, Poland, described its unique pharmacokinetics. Their presentations highlighted the unique traits that have ensured that bilastine is the only second-generation antihistamine to meet most of the desired features of an ideal drug described by international guidelines such as ARIA (Allergic Rhinitis and its Impact of Asthma), most notably its rapid onset of action and long-lasting effect, which are achieved without sedation.
Dr. Joseph Delano Fule Robles, 6 months ago

Researchers from the US recently demonstrated synergistic effects of topical calcipotriol and 5-fluorouracil (5-FU) for the treatment of actinic keratosis, a known precursor to squamous cell carcinoma (SCC) of the skin.